GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss

TUESDAY, Jan. 21, 2025-- For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and...